Patents by Inventor Genbei Wang

Genbei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING NASH USING A LONG-ACTING MUTANT HUMAN FIBROBLAST GROWTH FACTOR
    Publication number: 20250042964
    Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPBG-CH2-N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO:1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.
    Type: Application
    Filed: October 18, 2024
    Publication date: February 6, 2025
    Applicant: TASLY BIOPHARMACEUTICALS CO., LTD.
    Inventors: Jian LI, Jun HAN, Xiaohui MA, Ping TAI, Genbei WANG, Xiaodan CAO, Ruijing HUANG, Yongjie JIN, Jing LI, Chen CHEN, Guoyong JIA, Yuanyuan WANG
  • Method of treating nash using a long-acting mutant human fibroblast growth factor
    Patent number: 12152059
    Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH2—N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO: 1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: November 26, 2024
    Assignee: TASLY BIOPHARMACEUTICALS CO., LTD.
    Inventors: Jian Li, Jun Han, Xiaohui Ma, Ping Tai, Genbei Wang, Xiaodan Cao, Ruijing Huang, Yongjie Jin, Jing Li, Chen Chen, Guoyong Jia, Yuanyuan Wang
  • METHOD OF TREATING NASH USING A LONG-ACTING MUTANT HUMAN FIBROBLAST GROWTH FACTOR
    Publication number: 20190367574
    Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH2—N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO:1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.
    Type: Application
    Filed: July 23, 2019
    Publication date: December 5, 2019
    Inventors: Jian Li, Jun Han, Xiaohui Ma, Ping Tai, Genbei Wang, Xiaodan Cao, Ruijing Huang, Yongjie Jin, Jing Li, Chen Chen, Guoyong Jia, Yuanyuan Wang
  • Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
    Patent number: 9889093
    Abstract: The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: February 13, 2018
    Assignee: Tasly Pharmaceutical Group Co., Ltd.
    Inventors: Henry Sun, Xiaohui Ma, Zhixin Guo, Sen Lin, Genbei Wang, Lulu Yan, Lihua Zhang, Shuiping Zhou, Shunnan Zhang
  • APPLICATION OF ANDROGRAPHOLIDE IN THE PREPARATION OF A PHARMACEUTICAL FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE, ANDROGRAPHOLIDE ENTERIC TARGETING MICROPELLET, AND METHOD FOR PREPARATION THEREOF
    Publication number: 20170224622
    Abstract: The present invention relates to an andrographolide enteric targeting micropellet and method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in the preparation of a pharmaceutical for treatment of inflammatory bowel disease.
    Type: Application
    Filed: March 27, 2017
    Publication date: August 10, 2017
    Inventors: Henry Sun, Xiaohui Ma, Zhixin Guo, Sen Lin, Genbei Wang, Lulu Yan, Lihua Zhang, Shuiping Zhou, Shunnan Zhang
  • APPLICATION OF ANDROGRAPHOLIDE IN THE PREPARATION OF A PHARMACEUTICAL FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE, ANDROGRAPHOLIDE ENTERIC TARGETING MICROPELLET, AND METHOD FOR PREPARATION THEREOF
    Publication number: 20170224623
    Abstract: The present invention relates to an andrographolide enteric targeting micropellet and method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in the preparation of a pharmaceutical for treatment of inflammatory bowel disease.
    Type: Application
    Filed: March 27, 2017
    Publication date: August 10, 2017
    Inventors: Henry Sun, Xiaohui Ma, Zhixin Guo, Sen Lin, Genbei Wang, Lulu Yan, Lihua Zhang, Shuiping Zhou, Shunnan Zhang
  • APPLICATION OF ANDROGRAPHOLIDE IN THE PREPARATION OF A PHARMACEUTICAL FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE, ANDROGRAPHOLIDE ENTERIC TARGETING MICROPELLET, AND METHOD FOR PREPARATION THEREOF
    Publication number: 20160175253
    Abstract: The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.
    Type: Application
    Filed: August 6, 2014
    Publication date: June 23, 2016
    Inventors: Henry Sun, Xiaohui Ma, Zhixin Guo, Sen Lin, Genbei Wang, Lulu Yan, Lihua Zhang, Shuiping Zhou, Shunnan Zhang